[Transfer factor as adjuvant immunotherapy in invasive cervix cancer. Report of a double-blind study].
From 1977 to 1982 a prospective randomized double-blind study comparing transfer-factor (TF) versus placebo was conducted in invasive cervical cancer patients after radical surgery and irradiation. The husbands of the cancer patients were selected as leukocyte donors for TF preparations. 60 patients entered the study; 28 patients received placebo and 32 patients received TF. The comparability of both collectives was excellent concerning age and tumor stage. One patient treated with TF died intercurrently. The rate of recurrence of cancer was 5 in the 31 TF-treated patients and 11 in the 28 patients receiving placebo, which was significantly different (p less than 0,05). This difference was even greater when only patients treated for at least 3 months were compared (3 recurrences in the TF-group and 11 recurrences in the placebo-group). Further aspects of this clear clinical results are discussed.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007167:Immunotherapy; D010919:Placebos; D011897:Random Allocation; D014165:Transfer Factor / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000628:therapy*
D010919:Placebos; D014165:Transfer Factor
Transferfaktor als adjuvante Immuntherapie beim invasiven Zervixkarzinom. Bericht über eine Doppelblindstudie.